Over the last 7 days, the U.S. market has dropped 3.0%, yet it remains up by 4.6% over the past year, with earnings forecasted to grow annually by 14%. In light of these conditions, identifying stocks with strong balance sheets and solid fundamentals becomes crucial for investors seeking growth opportunities. Penny stocks, often representing smaller or newer companies, may seem like a relic from earlier market trends but continue to offer potential for significant upside at lower price points.

Top 10 Penny Stocks In The United States

Click here to see the full list of 791 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

iCAD

Simply Wall St Financial Health Rating: ★★★★★★

Overview: iCAD, Inc. operates in the United States, focusing on AI-powered cancer detection solutions, with a market cap of $52.46 million.

Operations: The company's revenue segment includes $19.61 million from its Detection business line.

Market Cap: $52.46M

iCAD, Inc., with a market cap of US$52.46 million, is navigating the penny stock landscape through strategic moves and financial resilience. The company recently announced a merger agreement with RadNet, Inc., valued at approximately US$100 million, which could enhance its market position pending shareholder approval. Despite being unprofitable, iCAD has shown revenue growth to US$19.61 million in 2024 and maintains a strong cash runway exceeding three years without debt obligations. The appointment of Mark Koeniguer as Chief Commercial Officer aims to drive further growth in AI-powered cancer detection solutions amidst high share price volatility and increased weekly volatility from 14% to 22%.

• Click here and access our complete financial health analysis report to understand the dynamics of iCAD.
• Explore iCAD's analyst forecasts in our growth report.

Silence Therapeutics

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Silence Therapeutics plc is a biotechnology company focused on discovering and developing novel siRNA molecules to inhibit gene expression in hematology, cardiovascular, and rare diseases, with a market cap of $132.23 million.

Operations: The company generates revenue primarily from its RNA Therapeutics segment, totaling $54.16 million.

Market Cap: $132.23M

Silence Therapeutics, with a market cap of $132.23 million, is navigating the biotech sector with a focus on siRNA molecules targeting hematology and cardiovascular diseases. Despite being unprofitable, it reported annual sales of £43.26 million in 2024, showing revenue growth from the previous year. The company remains debt-free and has sufficient cash runway extending into 2027, contingent on securing a partner for its zerlasiran Phase 3 study. Recent strategic moves include prioritizing divesiran development for rare conditions and filing a shelf registration to potentially raise $43.86 million through American Depositary Shares offerings amidst high share price volatility.

• Unlock comprehensive insights into our analysis of Silence Therapeutics stock in this financial health report.
• Learn about Silence Therapeutics' future growth trajectory here.

Texas Mineral Resources

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Texas Mineral Resources Corp. engages in the acquisition, exploration, and development of mineral properties in the United States with a market cap of $59.09 million.

Operations: Texas Mineral Resources Corp. currently does not report any revenue segments.

Market Cap: $59.09M

Texas Mineral Resources Corp., with a market cap of US$59.09 million, is currently pre-revenue, focusing on mineral exploration and development. The company has sufficient short-term assets to cover its liabilities and maintains more cash than debt, although its debt-to-equity ratio has increased over the past five years. Despite being unprofitable with increasing losses, Texas Mineral Resources recently secured US$848,000 through convertible promissory notes to bolster its financial position. However, recent executive resignations due to project delays signal potential operational challenges ahead. The stock remains highly volatile with a 22% increase in weekly volatility over the past year.

• Click here to discover the nuances of Texas Mineral Resources with our detailed analytical financial health report.
• Examine Texas Mineral Resources' past performance report to understand how it has performed in prior years.

Key Takeaways

• Unlock our comprehensive list of 791 US Penny Stocks by clicking here.
• Ready For A Different Approach? AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqCM:ICAD NasdaqGM:SLN and OTCPK:TMRC.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com